An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIIb, multicenter, open-label, extension study available to subjects who
successfully complete Study Q2143g and have not participated in Study Q2195g. Subjects should
be registered via the IVRS (Interactive Voice Response System) within 48 hours prior to their
baseline visit. All subjects in this study will be treated with Xolair for 24 weeks. Subjects
in the New Treatment Group may require additional visits for study drug injections (as
frequently as every 2 weeks). Data collection during these additional visits will be limited
to the assessment of adverse events. The study will evaluate all serious and nonserious
adverse events, laboratory assessments, data on asthma exacerbations, and concomitant
medication usage.